News  >  Breaking News  >  Athenex, a US-China Cancer Company, Stages $66 Million US IPO

Athenex, a US-China Cancer Company, Stages $66 Million US IPO

By Editing NAI
06/16/2017 4:10 a.m.

Athenex, a US-China cancer biopharma, completed a $66 million IPO on the NASDAQ exchange. Although that was the low end of the expected range, the company's shares have climbed 24% since they began trading. Athenex is developing a two-drug combination that would allow oral administration of common IV chemotherapies. The company is based in Buffalo, New York. It has partnered with New York State officials to build facilities there and with Chongqing to build a China manufacturing plant. It also has an R&D lab in Hong Kong.

Source: ChinaBio Today



Comments

No Comments


Please to leave a comment.